Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.
Identifieur interne : 001104 ( PubMed/Corpus ); précédent : 001103; suivant : 001105Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.
Auteurs : Stewart A. Factor ; N Kyle Steenland ; Donald S. Higgins ; Eric S. Molho ; Denise M. Kay ; Jennifer Montimurro ; Ami R. Rosen ; Cyrus P. Zabetian ; Haydeh PayamiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Age Factors, Aged, Apolipoproteins E (genetics), Cognition Disorders (etiology), Community Health Planning, Female, Humans, Logistic Models, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (genetics), Polymorphism, Single Nucleotide (genetics), Psychotic Disorders (etiology), Psychotic Disorders (genetics), Risk Factors, Severity of Illness Index, alpha-Synuclein (genetics), tau Proteins (genetics).
- MESH :
- chemical , genetics : Apolipoproteins E, alpha-Synuclein, tau Proteins.
- complications : Parkinson Disease.
- etiology : Cognition Disorders, Psychotic Disorders.
- genetics : Parkinson Disease, Polymorphism, Single Nucleotide, Psychotic Disorders.
- Age Factors, Aged, Community Health Planning, Female, Humans, Logistic Models, Male, Middle Aged, Risk Factors, Severity of Illness Index.
Abstract
Our aim was to examine disease-related and genetic correlates of the development of psychotic symptoms in a large population of patients with Parkinson's disease. We studied 500 patients with Parkinson's disease from the NeuroGenetics Research Consortium using logistic regression models. Predictors were demographic, clinical (motor/nonmotor features), and genetic, measured as continuous or dichotomous variables. Continuous measures were divided into population-based tertiles. Results are given as odds ratios (95% confidence intervals) for dichotomous variables and by ascending tertile for continuous variables. Psychotic symptoms were associated with increasing age: 4.86 (1.62-14.30) and 6.25 (2.09-18.74) (test for trend: P = 0.01); and duration of disease: 3.81 (1.23-11.76) and 5.33 (1.68-16.89) (test for trend: P = 0.03). For nonmotor features, we demonstrated positive trends with depression: 1.31 (0.47-3.61) and 5.01 (2.04-12.33) (test for trend: P < 0.0001); cognitive dysfunction: 0.69 (0.26-1.84) and 2.51 (1.00-6.29) (test for trend: P = 0.03); and an excess for those with sleep disorders: 2.00 (1.03-3.89) (P = 0.04). Psychotic symptoms were not associated with tremor or postural instability scores, but there was an association with freezing of gait: 3.83 (1.67-8.75) (P < 0.002). Psychotic symptoms were not associated with the presence of any examined polymorphisms in the apolipoprotein, alpha-synuclein, or microtubule associated protein tau genes. This is the largest study to examine correlates of psychotic symptoms in Parkinson's disease. We discovered a novel association with freezing of gait. We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders.
DOI: 10.1002/mds.23806
PubMed: 21714002
Links to Exploration step
pubmed:21714002Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name><affiliation><nlm:affiliation>Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA. sfactor@emory.edu</nlm:affiliation></affiliation></author><author><name sortKey="Steenland, N Kyle" sort="Steenland, N Kyle" uniqKey="Steenland N" first="N Kyle" last="Steenland">N Kyle Steenland</name></author><author><name sortKey="Higgins, Donald S" sort="Higgins, Donald S" uniqKey="Higgins D" first="Donald S" last="Higgins">Donald S. Higgins</name></author><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S" last="Molho">Eric S. Molho</name></author><author><name sortKey="Kay, Denise M" sort="Kay, Denise M" uniqKey="Kay D" first="Denise M" last="Kay">Denise M. Kay</name></author><author><name sortKey="Montimurro, Jennifer" sort="Montimurro, Jennifer" uniqKey="Montimurro J" first="Jennifer" last="Montimurro">Jennifer Montimurro</name></author><author><name sortKey="Rosen, Ami R" sort="Rosen, Ami R" uniqKey="Rosen A" first="Ami R" last="Rosen">Ami R. Rosen</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus P" last="Zabetian">Cyrus P. Zabetian</name></author><author><name sortKey="Payami, Haydeh" sort="Payami, Haydeh" uniqKey="Payami H" first="Haydeh" last="Payami">Haydeh Payami</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1002/mds.23806</idno><idno type="RBID">pubmed:21714002</idno><idno type="pmid">21714002</idno><idno type="wicri:Area/PubMed/Corpus">001104</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name><affiliation><nlm:affiliation>Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA. sfactor@emory.edu</nlm:affiliation></affiliation></author><author><name sortKey="Steenland, N Kyle" sort="Steenland, N Kyle" uniqKey="Steenland N" first="N Kyle" last="Steenland">N Kyle Steenland</name></author><author><name sortKey="Higgins, Donald S" sort="Higgins, Donald S" uniqKey="Higgins D" first="Donald S" last="Higgins">Donald S. Higgins</name></author><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S" last="Molho">Eric S. Molho</name></author><author><name sortKey="Kay, Denise M" sort="Kay, Denise M" uniqKey="Kay D" first="Denise M" last="Kay">Denise M. Kay</name></author><author><name sortKey="Montimurro, Jennifer" sort="Montimurro, Jennifer" uniqKey="Montimurro J" first="Jennifer" last="Montimurro">Jennifer Montimurro</name></author><author><name sortKey="Rosen, Ami R" sort="Rosen, Ami R" uniqKey="Rosen A" first="Ami R" last="Rosen">Ami R. Rosen</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus P" last="Zabetian">Cyrus P. Zabetian</name></author><author><name sortKey="Payami, Haydeh" sort="Payami, Haydeh" uniqKey="Payami H" first="Haydeh" last="Payami">Haydeh Payami</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Apolipoproteins E (genetics)</term><term>Cognition Disorders (etiology)</term><term>Community Health Planning</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (genetics)</term><term>Polymorphism, Single Nucleotide (genetics)</term><term>Psychotic Disorders (etiology)</term><term>Psychotic Disorders (genetics)</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>alpha-Synuclein (genetics)</term><term>tau Proteins (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apolipoproteins E</term><term>alpha-Synuclein</term><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term><term>Polymorphism, Single Nucleotide</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Community Health Planning</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our aim was to examine disease-related and genetic correlates of the development of psychotic symptoms in a large population of patients with Parkinson's disease. We studied 500 patients with Parkinson's disease from the NeuroGenetics Research Consortium using logistic regression models. Predictors were demographic, clinical (motor/nonmotor features), and genetic, measured as continuous or dichotomous variables. Continuous measures were divided into population-based tertiles. Results are given as odds ratios (95% confidence intervals) for dichotomous variables and by ascending tertile for continuous variables. Psychotic symptoms were associated with increasing age: 4.86 (1.62-14.30) and 6.25 (2.09-18.74) (test for trend: P = 0.01); and duration of disease: 3.81 (1.23-11.76) and 5.33 (1.68-16.89) (test for trend: P = 0.03). For nonmotor features, we demonstrated positive trends with depression: 1.31 (0.47-3.61) and 5.01 (2.04-12.33) (test for trend: P < 0.0001); cognitive dysfunction: 0.69 (0.26-1.84) and 2.51 (1.00-6.29) (test for trend: P = 0.03); and an excess for those with sleep disorders: 2.00 (1.03-3.89) (P = 0.04). Psychotic symptoms were not associated with tremor or postural instability scores, but there was an association with freezing of gait: 3.83 (1.67-8.75) (P < 0.002). Psychotic symptoms were not associated with the presence of any examined polymorphisms in the apolipoprotein, alpha-synuclein, or microtubule associated protein tau genes. This is the largest study to examine correlates of psychotic symptoms in Parkinson's disease. We discovered a novel association with freezing of gait. We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21714002</PMID><DateCreated><Year>2011</Year><Month>10</Month><Day>24</Day></DateCreated><DateCompleted><Year>2012</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>2190-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23806</ELocationID><Abstract><AbstractText>Our aim was to examine disease-related and genetic correlates of the development of psychotic symptoms in a large population of patients with Parkinson's disease. We studied 500 patients with Parkinson's disease from the NeuroGenetics Research Consortium using logistic regression models. Predictors were demographic, clinical (motor/nonmotor features), and genetic, measured as continuous or dichotomous variables. Continuous measures were divided into population-based tertiles. Results are given as odds ratios (95% confidence intervals) for dichotomous variables and by ascending tertile for continuous variables. Psychotic symptoms were associated with increasing age: 4.86 (1.62-14.30) and 6.25 (2.09-18.74) (test for trend: P = 0.01); and duration of disease: 3.81 (1.23-11.76) and 5.33 (1.68-16.89) (test for trend: P = 0.03). For nonmotor features, we demonstrated positive trends with depression: 1.31 (0.47-3.61) and 5.01 (2.04-12.33) (test for trend: P < 0.0001); cognitive dysfunction: 0.69 (0.26-1.84) and 2.51 (1.00-6.29) (test for trend: P = 0.03); and an excess for those with sleep disorders: 2.00 (1.03-3.89) (P = 0.04). Psychotic symptoms were not associated with tremor or postural instability scores, but there was an association with freezing of gait: 3.83 (1.67-8.75) (P < 0.002). Psychotic symptoms were not associated with the presence of any examined polymorphisms in the apolipoprotein, alpha-synuclein, or microtubule associated protein tau genes. This is the largest study to examine correlates of psychotic symptoms in Parkinson's disease. We discovered a novel association with freezing of gait. We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders.</AbstractText><CopyrightInformation>Copyright © 2011 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Factor</LastName><ForeName>Stewart A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA. sfactor@emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenland</LastName><ForeName>N Kyle</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Donald S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Molho</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Denise M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Montimurro</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Ami R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Zabetian</LastName><ForeName>Cyrus P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS036960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS36960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2005 Oct;252(10):1223-8</RefSource><PMID Version="1">15834642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Aug;20(8):989-94</RefSource><PMID Version="1">15852364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Mar 27;56(6):730-6</RefSource><PMID Version="1">11274306</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Apr;123 ( Pt 4):733-45</RefSource><PMID Version="1">10734005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Genet. 2005 Dec;118(3-4):322-30</RefSource><PMID Version="1">16189709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 2001 May;16(5):528-36</RefSource><PMID Version="1">11376470</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):727-33</RefSource><PMID Version="1">11385004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8</RefSource><PMID Version="1">11385005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Dec 11;57(11):2078-82</RefSource><PMID Version="1">11739829</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2002 Jan;59(1):102-12</RefSource><PMID Version="1">11790237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenetics. 2003 Jun;13(6):365-9</RefSource><PMID Version="1">12777967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Jun 10;60(11):1750-5</RefSource><PMID Version="1">12796525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Jun 10;60(11):1756-61</RefSource><PMID Version="1">12796526</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Jan 10;66(1):93-8</RefSource><PMID Version="1">16401853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Apr;21(4):519-23</RefSource><PMID Version="1">16250030</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2006 May;63(5):713-6</RefSource><PMID Version="1">16682540</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 May;21(5):668-72</RefSource><PMID Version="1">16450355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Aug;21(8):1123-30</RefSource><PMID Version="1">16637023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2006 Oct;12(7):427-31</RefSource><PMID Version="1">16797214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2007 Jan 31;252(2):130-4</RefSource><PMID Version="1">17196621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 2007 Jun;22(6):601-4</RefSource><PMID Version="1">17450623</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jul 10;69(2):187-95</RefSource><PMID Version="1">17620552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2007 Jul 18;422(3):228-31</RefSource><PMID Version="1">17614196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2007 Aug;62(2):137-44</RefSource><PMID Version="1">17514749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Genet. 2008 Apr;123(3):257-65</RefSource><PMID Version="1">18210157</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurotherapeutics. 2008 Apr;5(2):164-80</RefSource><PMID Version="1">18394561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Apr 30;23(6):837-44</RefSource><PMID Version="1">18307261</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1222-30</RefSource><PMID Version="1">18404644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 May 15;24(7):1042-7</RefSource><PMID Version="1">19353712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2010 Feb 15;289(1-2):12-7</RefSource><PMID Version="1">19740486</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Neurosci. 2010 Aug;120(8):538-43</RefSource><PMID Version="1">20615057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2010 Nov;16(9):553-60</RefSource><PMID Version="1">20538500</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Nov 16;75(20):1773-9</RefSource><PMID Version="1">20962287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2011 May;82(5):564-8</RefSource><PMID Version="1">20884673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Jan 27;62(2):177-80</RefSource><PMID Version="1">14745050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Aug;61(8):1280-4</RefSource><PMID Version="1">15313848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1991 Aug;14(4):283-95</RefSource><PMID Version="1">1680556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4</RefSource><PMID Version="1">1564476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1995 Apr;45(4):669-71</RefSource><PMID Version="1">7723953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1996 Dec;53(12):1265-8</RefSource><PMID Version="1">8970453</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1997 Oct;42(4):655-8</RefSource><PMID Version="1">9382478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1998 Feb;50(2):515-7</RefSource><PMID Version="1">9484386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Mar 11;340(10):757-63</RefSource><PMID Version="1">10072410</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1999 May;45(5):611-7</RefSource><PMID Version="1">10319883</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 May;56(5):595-601</RefSource><PMID Version="1">10328255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2509-18</RefSource><PMID Version="1">15590953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Feb;20(2):212-7</RefSource><PMID Version="1">15390044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Dec 27;65(12):1863-72</RefSource><PMID Version="1">16237129</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001057">Apolipoproteins E</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018672">Community Health Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051844">alpha-Synuclein</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016875">tau Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS482898</OtherID><OtherID Source="NLM">PMC4216677</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23806</ArticleId><ArticleId IdType="pubmed">21714002</ArticleId><ArticleId IdType="pmc">PMC4216677</ArticleId><ArticleId IdType="mid">NIHMS482898</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001104 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001104 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21714002
|texte= Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21714002" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |